Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML

Po Yee Mak(The University of Texas MD Anderson Cancer Center), B. Z. Carter(The University of Texas MD Anderson Cancer Center), Vivian Ruvolo(Hormel (United States)), W. Wei(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Duncan H. Mak(The University of Texas MD Anderson Cancer Center), Hong Mu(Tianjin First Center Hospital), Peter P. Ruvolo(The University of Texas MD Anderson Cancer Center), Ya-Zhou Shi(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Rodrigo Jácamo, Michael Andreeff(The University of Texas MD Anderson Cancer Center), Jared K. Burks(The University of Texas MD Anderson Cancer Center)
APOPTOSIS
December 12, 2013
10.1007/s10495-013-0954-z
Cited by 27

Related Papers

An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
|Blood|2006|691
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
|Blood|2001|570